Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: Anticancer Drugs. 2013 Jun;24(5):484–493. doi: 10.1097/CAD.0b013e32835ffdbb

Figure 5. Effect of EHMT2 inhibition on caspase activity.

Figure 5

(A) Caspase 3 activities were measured in vehicle or BIX-01294 treated LA1-55n cells. The LA1-55n cells were treated with BIX-01294 at the concentrations of 1, 2.5, 5 and 10 μg/ml. Staurosporin (STS) at the concentration of 1 μM was used as a positive control for activation of caspase activity. (B) Caspase 8 activities were measured in vehicle or BIX-01294 treated LA1-55n cells. The LA1-55n cells were treated with BIX-01294 at the concentrations of 1, 2.5, 5 and 10 μg/ml. Staurosporin (STS) at the concentration of 1 μM was used as a positive control for activation of caspase activity. * represents a statistical significant difference (p<0.01) between the vehicle- and BIX-01294-treated cells. (C) LA1-55n cells were treated with various concentrations of doxorubicin (0.012, 0.12, 1.2, 12, 120 ng/ml) and proliferation was assessed by trypan blue exclusion. (D) 40 μM of LETD caspase 8 inhibitor was added to the media 30 min prior to BIX-01294 treatment, and cells were incubated in10 μM of BIX-01294 for 24 h. And trypan blue exclusion was performed to determine the relative number of dead cells. (E) LA1-55n cells were treated with either 12 ng/ml doxorubicin, 5 μg/ml BIX-01294 or in combination with 5 μg/ml BIX-01294 for 24 h. Trypan blue exclusion was performed to determine the percentage of dead cells.